We use cookies to improve the performance of our site and optimize it for our users. Customize Cookie Preferences

Sign Up Today and Learn More About Pendulum Therapeutics Stock

Invest in or calculate the value of your shares in Pendulum Therapeutics or other pre-IPO companies through EquityZen's platform.

Get Started

Pendulum Therapeutics Stock (PENT)

Pendulum Therapeutics is a biotechnology firm improving health through products targeting the microbiome.

About Pendulum Therapeutics Stock

Founded

2013

Headquarters

San Francisco, CA, US

Industries

Software, Artificial Intelligence, Data and Analytics

Pendulum Therapeutics believes therapies developed using evidence-based microbiome science and DNA sequencing can help heal the body from within. Armed with 13 patents and 42 pending, the company introduced its flagship product Pendulum Glucose Control, a medical probiotic, in 2020 and demonstrated its efficacy in lowering blood sugar spikes and reducing A1C in a published clinical trial. Founded in 2013 by a diverse team of scientists with deep microbiology, biochemistry, computational, and clinical expertise, Pendulum has raised $111 million to date from Meritech Capital, Sequoia Capital, True Ventures, Khosla Ventures, AME Cloud Ventures and Mayo Clinic among others. Pendulum Therapeutics is headquartered in San Francisco.

Pendulum Therapeutics Press Mentions

Stay in the know about the latest news on Pendulum Therapeutics

Pendulum Therapeutics Management

Leadership team at Pendulum Therapeutics

COO

Mohan Iyer

Chief Medical Officer

Adam Perlman

Locked Features

Join now and verify your accreditation status to gain access to:

  • Pendulum Therapeutics current valuation
  • Pendulum Therapeutics stock price
  • Available deals in Pendulum Therapeutics and all other companies
  • Deal offering documents
  • EquityZen's proprietary data and insights, including
    • Cap tables, which include funding history by Share Class and Liquidity Preferences
    • Company Highlights
    • Business Model
    • Risk Factors
Join Now

How to invest in Pendulum Therapeutics stock?

Accredited investors can buy pre-IPO stock in companies like Pendulum Therapeutics through EquityZen funds. These investments are made available by existing Pendulum Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.

How to sell Pendulum Therapeutics stock?

Shareholders can sell their Pendulum Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.

If I invest, how do I exit my investment?

There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.

Why choose EquityZen?

Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."